Technology

Build around patent protected chemiluminescent enzyme substrates.

In order to fulfill our mission to bring the lab to the patient, the focus was on the portability of ENZYCARD technology without sacrificing the quality of the assays.



Watch our video

Portable

ENZYPAD has only 4 components: blood sampling device (TAP in case of haemophilia), microfluidic cartridge (ENZYCARD), processor (ENZYPAD) and a mobile phone with the ENZY app. As it is the size of a small tablet, ENZYPAD is easily portable and fits into a small backpack together with several ENZYCARDs.

High quality

Each ENZYCARD contains reagents and appropriate controls to perform several coagulation tests in parallel on a single blood sample. The results have the same quality as if performed on a large instrument in a specialized laboratory and are available in real-time right next to the patient who can get the optimal therapy without any delay.

Multi parameter

In order to find the cause of a bleed, in most cases it is necessary to determine several parameters simultaneously. As a single ENZYCARD can handle up to sixteen tests in parallel, there is ample space for multiple assays and corresponding controls.

Cloud access

The ENZYPAD will encrypt the data of the test results and transfer them via a Bluetooth connection to a mobile phone app, that will place the data in the cloud where anyone with the appropriate credentials can access them.

Technology

The first ENZYPAD products will be focused on blood coagulation, the core expertise of the company. The technology can be however by applied much more broadly in collaboration with partners that have expertise in different fields.

About blood coagulation

Coagulation begins almost instantly after an injury to the blood vessel has damaged the lining of the blood vessel. Exposure of blood initiates two processes: changes in platelets, and the exposure of tissue factor to plasma factor VII, which ultimately leads to cross-linked fibrin formation. Platelets immediately form a plug at the site of injury; this is called primary hemostasis. Secondary hemostasis occurs simultaneously: additional coagulation factors respond in a cascade to form fibrin strands, which strengthen the platelet plug.

Join us on our journey

Enzyre is now preparing to raise €10M in its Series A investment round. The proceeds will be used to (a) finalize the development of the ENZYPAD en ENZYCARD Hemophilia A, (b) manufacture the portable instrument & disposable, and (c) perform studies to obtain regulatory approval in EU & US. The product will be commercialized worldwide through our pharma partner. Interested candidate investors are encouraged to contact us at investors@enzyre.com.

Get involved